v3.26.1
COMMITMENTS AND CONTINGENCIES (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2026
USD ($)
May 31, 2023
USD ($)
Aug. 31, 2022
USD ($)
product
Dec. 31, 2021
USD ($)
Dec. 31, 2016
USD ($)
product
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Loss Contingencies [Line Items]                      
Prepaid expenses and other current assets           $ 6,398,000     $ 6,398,000   $ 4,733,000
Research and development           9,957,000 $ 6,465,000   $ 21,137,000 $ 13,123,000  
Loss on fraudulent funds transfer               $ 1,800,000      
Gensaic, Inc                      
Loss Contingencies [Line Items]                      
Payments to acquire investment     $ 5,100,000                
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                      
Loss Contingencies [Line Items]                      
Advance written notice required to terminate agreement                 90 days    
Northwestern University | License Agreement                      
Loss Contingencies [Line Items]                      
Upfront non-creditable one-time license issuance fee payment         $ 75,000            
Annual license maintenance fee payable         20,000            
Consideration payable for rights grant (up to)         $ 5,300,000            
Royalty obligation period         10 years            
Minimum number of product covered under license agreement | product         1            
AstraZeneca                      
Loss Contingencies [Line Items]                      
Upfront cash payment       $ 5,000,000.0              
Shares issued in license agreement       $ 7,300,000              
Days immediately preceding the execution date       30 days              
License agreement milestone payments (up to)       $ 203,000,000.0              
First payment due upon completion of first phase       $ 3,000,000.0              
Gensaic, Inc                      
Loss Contingencies [Line Items]                      
Remaining prepaid research $ 1,000,000.0                    
Gensaic, Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                      
Loss Contingencies [Line Items]                      
License agreement milestone payments (up to)     452,000,000.0                
Research plan and budget, expected costs   $ 3,500,000 $ 3,000,000.0                
Prepaid expenses and other current assets           1,000,000.0     $ 1,000,000.0   $ 1,000,000.0
Research and development           $ 0 $ 0   $ 0 $ 0  
Developmental milestone approvals, number of products (at least) | product     3